



## Complete Summary

### TITLE

Hematology: percentage of patients aged 18 years and older with a diagnosis of chronic lymphocytic leukemia (CLL) who had baseline flow cytometry studies performed.

### SOURCE(S)

American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Jan. 22 p. [10 references]

## Measure Domain

### PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### SECONDARY MEASURE DOMAIN

Does not apply to this measure

## Brief Abstract

### DESCRIPTION

This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of chronic lymphocytic leukemia (CLL) who had baseline flow cytometry studies performed.

### RATIONALE

Due to the distinct pattern of protein antigens expressed in chronic lymphocytic leukemia (CLL), flow cytometry should be performed in order to confirm the diagnosis, correctly characterize the pathological cells, and determine prognosis. In some instances, flow cytometry may also offer additional therapeutically relevant information.\*

\*The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

As with all the lymphoid neoplasms, adequate hematopathologic review is essential to establish an accurate diagnosis of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). ...a combination of morphologic and flow cytometric studies may provide adequate information to provide a diagnosis. This is particularly true for the diagnosis of CLL. Flow cytometric studies performed on patients with leukemic cell burden include kappa/lambda to [assess] clonality...Distinguishing CLL/SLL from mantle cell lymphoma is essential. (National Comprehensive Cancer Network [NCCN])

## **PRIMARY CLINICAL COMPONENT**

Chronic lymphocytic leukemia (CLL); flow cytometry

## **DENOMINATOR DESCRIPTION**

All patients aged 18 years and older with a diagnosis of chronic lymphocytic leukemia (CLL) (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

## **NUMERATOR DESCRIPTION**

Patients who had baseline flow cytometry\* studies performed

\*Baseline flow cytometry studies refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.

## **Evidence Supporting the Measure**

### **EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

## **Evidence Supporting Need for the Measure**

### **NEED FOR THE MEASURE**

Unspecified

## **State of Use of the Measure**

### **STATE OF USE**

Current routine use

### **CURRENT USE**

Internal quality improvement  
National reporting

## Application of Measure in its Current Use

### **CARE SETTING**

Ambulatory Care  
Physician Group Practices/Clinics

### **PROFESSIONALS RESPONSIBLE FOR HEALTH CARE**

Advanced Practice Nurses  
Physician Assistants  
Physicians

### **LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED**

Individual Clinicians

### **TARGET POPULATION AGE**

Age greater than or equal to 18 years

### **TARGET POPULATION GENDER**

Either male or female

### **STRATIFICATION BY VULNERABLE POPULATIONS**

Unspecified

## Characteristics of the Primary Clinical Component

### **INCIDENCE/PREVALENCE**

Unspecified

### **ASSOCIATION WITH VULNERABLE POPULATIONS**

Unspecified

### **BURDEN OF ILLNESS**

Unspecified

### **UTILIZATION**

Unspecified

### **COSTS**

Unspecified

## Institute of Medicine National Healthcare Quality Report Categories

### IOM CARE NEED

Living with Illness

### IOM DOMAIN

Effectiveness

## Data Collection for the Measure

### CASE FINDING

Users of care only

### DESCRIPTION OF CASE FINDING

All patients aged 18 years and older with a diagnosis of chronic lymphocytic leukemia (CLL)

### DENOMINATOR SAMPLING FRAME

Patients associated with provider

### DENOMINATOR INCLUSIONS/EXCLUSIONS

#### Inclusions

All patients aged 18 years and older with a diagnosis of chronic lymphocytic leukemia (CLL)

#### Exclusions

- Documentation of medical reason(s) for not performing baseline flow cytometry studies
- Documentation of patient reason(s) for not performing baseline flow cytometry studies
- Documentation of system reason(s) for not performing baseline flow cytometry studies

### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

### DENOMINATOR (INDEX) EVENT

Clinical Condition

## **DENOMINATOR TIME WINDOW**

Time window is a single point in time

## **NUMERATOR INCLUSIONS/EXCLUSIONS**

### **Inclusions**

Patients who had baseline flow cytometry\* studies performed

\*Baseline flow cytometry studies refer to testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.

### **Exclusions**

None

## **MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS**

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## **NUMERATOR TIME WINDOW**

Episode of care

## **DATA SOURCE**

Administrative data  
Medical record

## **LEVEL OF DETERMINATION OF QUALITY**

Individual Case

## **PRE-EXISTING INSTRUMENT USED**

Unspecified

## **Computation of the Measure**

## **SCORING**

Rate

## **INTERPRETATION OF SCORE**

Better quality is associated with a higher score

## **ALLOWANCE FOR PATIENT FACTORS**

Unspecified

## **STANDARD OF COMPARISON**

Internal time comparison

## **Evaluation of Measure Properties**

## **EXTENT OF MEASURE TESTING**

Unspecified

## **Identifying Information**

## **ORIGINAL TITLE**

Measure #4: chronic lymphocytic leukemia (CLL) - baseline flow cytometry.

## **MEASURE COLLECTION**

[The Physician Consortium for Performance Improvement® Measurement Sets](#)

## **MEASURE SET NAME**

[Hematology Physician Performance Measurement Set](#)

## **SUBMITTER**

American Medical Association on behalf of the American Society of Hematology and the Physician Consortium for Performance Improvement®

## **DEVELOPER**

American Society of Hematology  
Physician Consortium for Performance Improvement®

## **FUNDING SOURCE(S)**

Unspecified

## **COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE**

Steven L. Allen, MD (*Co-Chair*); William E. Golden, MD (*Co-Chair*); Kenneth Adler, MD; Daniel Halevy, MD; Stuart Henochowicz, MD, MBA; Timothy Miley, MD; David Morris, MD; John M. Rainey, MD; Samuel M. Silver, MD, PhD; Lawrence Solberg, Jr., MD, PhD

Mila Becker, Esq., American Society of Hematology; Pamela Ferraro, MS, American Society of Hematology; Sue Frechette, BSN, MBA (Consultant), American Society of Hematology

Karen S. Kmetik, PhD, American Medical Association; Samantha Tierney, MPH, American Medical Association

Kristen McNiff, MPH, American Society of Clinical Oncology

Emily Wilson, American Society for Therapeutic Radiology and Oncology

Hildy Dillon, MPH, Leukemia and Lymphoma Society; Mary Grace Pagaduan, MPH, Leukemia and Lymphoma Society

Sue Nedza, MD, MBA, FACEP, Centers for Medicare & Medicaid Services; Sylvia Publ, MBA, RHIA, Centers for Medicare & Medicaid Services

Rebecca Kresowik, Consortium Consultant; Timothy F. Kresowik, MD, Consortium Consultant

#### **FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST**

Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

#### **ENDORSER**

National Quality Forum

#### **INCLUDED IN**

Ambulatory Care Quality Alliance  
Physician Quality Reporting Initiative

#### **ADAPTATION**

Measure was not adapted from another source.

#### **RELEASE DATE**

2007 Jan

#### **MEASURE STATUS**

This is the current release of the measure.

#### **SOURCE(S)**

American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Jan. 22 p. [10 references]

## **MEASURE AVAILABILITY**

The individual measure, "Measure #4: Chronic Lymphocytic Leukemia (CLL) - Baseline Flow Cytometry," is published in the "Hematology Physician Performance Measurement Set." This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement® Web site: [www.physicianconsortium.org](http://www.physicianconsortium.org).

For further information, please contact AMA staff by e-mail at [cqi@ama-assn.org](mailto:cqi@ama-assn.org).

## **NQMC STATUS**

This NQMC summary was completed by ECRI Institute on September 13, 2007. The information was verified by the measure developer on October 26, 2007.

## **COPYRIGHT STATEMENT**

© Copyright 2006-7 American Medical Association and American Society of Hematology. All Rights Reserved.

## **Disclaimer**

### **NQMC DISCLAIMER**

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.



© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

